nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—OPRD1—epilepsy syndrome	0.104	0.314	CbGaD
Buprenorphine—OPRM1—epilepsy syndrome	0.0793	0.241	CbGaD
Buprenorphine—ABCG2—epilepsy syndrome	0.0527	0.16	CbGaD
Buprenorphine—CYP2C19—epilepsy syndrome	0.0414	0.126	CbGaD
Buprenorphine—CYP2D6—epilepsy syndrome	0.0307	0.0931	CbGaD
Buprenorphine—CYP2C18—Clobazam—epilepsy syndrome	0.0225	0.0522	CbGbCtD
Buprenorphine—ABCB1—epilepsy syndrome	0.0219	0.0665	CbGaD
Buprenorphine—CYP2C18—Phenytoin—epilepsy syndrome	0.0167	0.0388	CbGbCtD
Buprenorphine—UGT1A9—Propofol—epilepsy syndrome	0.0156	0.0362	CbGbCtD
Buprenorphine—CYP2C18—Propofol—epilepsy syndrome	0.0156	0.0362	CbGbCtD
Buprenorphine—CYP2C18—Phenobarbital—epilepsy syndrome	0.0149	0.0345	CbGbCtD
Buprenorphine—CYP2C18—Diazepam—epilepsy syndrome	0.0141	0.0328	CbGbCtD
Buprenorphine—UGT1A9—Valproic Acid—epilepsy syndrome	0.0111	0.0258	CbGbCtD
Buprenorphine—CYP2C18—Valproic Acid—epilepsy syndrome	0.0111	0.0258	CbGbCtD
Buprenorphine—CYP2A6—Amobarbital—epilepsy syndrome	0.0102	0.0236	CbGbCtD
Buprenorphine—CYP2A6—Propofol—epilepsy syndrome	0.00757	0.0176	CbGbCtD
Buprenorphine—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.00739	0.0172	CbGbCtD
Buprenorphine—CYP2A6—Phenobarbital—epilepsy syndrome	0.00724	0.0168	CbGbCtD
Buprenorphine—CYP2C8—Trimethadione—epilepsy syndrome	0.00661	0.0153	CbGbCtD
Buprenorphine—CYP2C8—Fosphenytoin—epilepsy syndrome	0.00621	0.0144	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Carbamazepine—epilepsy syndrome	0.00619	0.0144	CbGbCtD
Buprenorphine—CYP3A7—Carbamazepine—epilepsy syndrome	0.00619	0.0144	CbGbCtD
Buprenorphine—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.00596	0.0138	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Phenytoin—epilepsy syndrome	0.00555	0.0129	CbGbCtD
Buprenorphine—CYP3A7—Phenytoin—epilepsy syndrome	0.00555	0.0129	CbGbCtD
Buprenorphine—CYP2C19—Felbamate—epilepsy syndrome	0.00554	0.0129	CbGbCtD
Buprenorphine—CYP2C19—Trimethadione—epilepsy syndrome	0.00554	0.0129	CbGbCtD
Buprenorphine—CYP2A6—Valproic Acid—epilepsy syndrome	0.00541	0.0125	CbGbCtD
Buprenorphine—ABCB1—Levetiracetam—epilepsy syndrome	0.00526	0.0122	CbGbCtD
Buprenorphine—CYP2C19—Fosphenytoin—epilepsy syndrome	0.00521	0.0121	CbGbCtD
Buprenorphine—CYP3A7—Phenobarbital—epilepsy syndrome	0.00495	0.0115	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Phenobarbital—epilepsy syndrome	0.00495	0.0115	CbGbCtD
Buprenorphine—CYP3A7—Midazolam—epilepsy syndrome	0.00488	0.0113	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Midazolam—epilepsy syndrome	0.00488	0.0113	CbGbCtD
Buprenorphine—CYP3A7—Diazepam—epilepsy syndrome	0.00469	0.0109	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Diazepam—epilepsy syndrome	0.00469	0.0109	CbGbCtD
Buprenorphine—CYP3A5—Carbamazepine—epilepsy syndrome	0.00464	0.0108	CbGbCtD
Buprenorphine—CYP2C9—Trimethadione—epilepsy syndrome	0.00461	0.0107	CbGbCtD
Buprenorphine—CYP2C19—Clobazam—epilepsy syndrome	0.00452	0.0105	CbGbCtD
Buprenorphine—CYP2C8—Carbamazepine—epilepsy syndrome	0.00446	0.0104	CbGbCtD
Buprenorphine—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00433	0.0101	CbGbCtD
Buprenorphine—CYP2C8—Primidone—epilepsy syndrome	0.00417	0.00967	CbGbCtD
Buprenorphine—CYP3A5—Phenytoin—epilepsy syndrome	0.00416	0.00966	CbGbCtD
Buprenorphine—CYP2C8—Phenytoin—epilepsy syndrome	0.004	0.00929	CbGbCtD
Buprenorphine—CYP2C19—Carbamazepine—epilepsy syndrome	0.00374	0.00869	CbGbCtD
Buprenorphine—CYP2C8—Propofol—epilepsy syndrome	0.00373	0.00866	CbGbCtD
Buprenorphine—CYP3A5—Phenobarbital—epilepsy syndrome	0.00371	0.00861	CbGbCtD
Buprenorphine—CYP3A5—Midazolam—epilepsy syndrome	0.00366	0.00849	CbGbCtD
Buprenorphine—ABCB1—Clobazam—epilepsy syndrome	0.00365	0.00846	CbGbCtD
Buprenorphine—CYP2C8—Phenobarbital—epilepsy syndrome	0.00357	0.00828	CbGbCtD
Buprenorphine—CYP3A5—Diazepam—epilepsy syndrome	0.00352	0.00816	CbGbCtD
Buprenorphine—ABCB1—Lamotrigine—epilepsy syndrome	0.00351	0.00814	CbGbCtD
Buprenorphine—CYP2C19—Primidone—epilepsy syndrome	0.0035	0.00811	CbGbCtD
Buprenorphine—CYP1A2—Carbamazepine—epilepsy syndrome	0.00345	0.00802	CbGbCtD
Buprenorphine—CYP2C8—Diazepam—epilepsy syndrome	0.00338	0.00785	CbGbCtD
Buprenorphine—CYP2C19—Phenytoin—epilepsy syndrome	0.00336	0.00779	CbGbCtD
Buprenorphine—CYP1A2—Primidone—epilepsy syndrome	0.00322	0.00748	CbGbCtD
Buprenorphine—CYP2C19—Propofol—epilepsy syndrome	0.00313	0.00727	CbGbCtD
Buprenorphine—CYP2C9—Carbamazepine—epilepsy syndrome	0.00311	0.00722	CbGbCtD
Buprenorphine—ABCB1—Carbamazepine—epilepsy syndrome	0.00302	0.00701	CbGbCtD
Buprenorphine—CYP2C19—Phenobarbital—epilepsy syndrome	0.00299	0.00695	CbGbCtD
Buprenorphine—CYP2C9—Primidone—epilepsy syndrome	0.00291	0.00674	CbGbCtD
Buprenorphine—CYP1A2—Propofol—epilepsy syndrome	0.00289	0.00671	CbGbCtD
Buprenorphine—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00288	0.00669	CbGbCtD
Buprenorphine—CYP2C19—Diazepam—epilepsy syndrome	0.00284	0.00658	CbGbCtD
Buprenorphine—CYP2C9—Phenytoin—epilepsy syndrome	0.00279	0.00648	CbGbCtD
Buprenorphine—CYP3A5—Valproic Acid—epilepsy syndrome	0.00277	0.00643	CbGbCtD
Buprenorphine—CYP2C19—Zonisamide—epilepsy syndrome	0.00277	0.00643	CbGbCtD
Buprenorphine—CYP1A2—Phenobarbital—epilepsy syndrome	0.00276	0.00641	CbGbCtD
Buprenorphine—ABCB1—Phenytoin—epilepsy syndrome	0.00271	0.00629	CbGbCtD
Buprenorphine—CYP3A4—Trimethadione—epilepsy syndrome	0.00268	0.00622	CbGbCtD
Buprenorphine—CYP3A4—Felbamate—epilepsy syndrome	0.00268	0.00622	CbGbCtD
Buprenorphine—CYP2C8—Valproic Acid—epilepsy syndrome	0.00267	0.00619	CbGbCtD
Buprenorphine—CYP1A2—Diazepam—epilepsy syndrome	0.00262	0.00608	CbGbCtD
Buprenorphine—CYP2C9—Propofol—epilepsy syndrome	0.0026	0.00604	CbGbCtD
Buprenorphine—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00252	0.00585	CbGbCtD
Buprenorphine—CYP2C9—Phenobarbital—epilepsy syndrome	0.00249	0.00577	CbGbCtD
Buprenorphine—ABCB1—Phenobarbital—epilepsy syndrome	0.00241	0.0056	CbGbCtD
Buprenorphine—ABCB1—Midazolam—epilepsy syndrome	0.00238	0.00553	CbGbCtD
Buprenorphine—CYP2D6—Propofol—epilepsy syndrome	0.00238	0.00553	CbGbCtD
Buprenorphine—CYP2C9—Diazepam—epilepsy syndrome	0.00236	0.00547	CbGbCtD
Buprenorphine—ABCB1—Diazepam—epilepsy syndrome	0.00229	0.00531	CbGbCtD
Buprenorphine—CYP3A4—Clonazepam—epilepsy syndrome	0.00228	0.00529	CbGbCtD
Buprenorphine—CYP2C19—Valproic Acid—epilepsy syndrome	0.00224	0.00519	CbGbCtD
Buprenorphine—CYP3A4—Clobazam—epilepsy syndrome	0.00218	0.00507	CbGbCtD
Buprenorphine—CYP1A2—Valproic Acid—epilepsy syndrome	0.00206	0.00479	CbGbCtD
Buprenorphine—CYP2C19—Topiramate—epilepsy syndrome	0.00202	0.00468	CbGbCtD
Buprenorphine—CYP2C9—Valproic Acid—epilepsy syndrome	0.00186	0.00432	CbGbCtD
Buprenorphine—CYP3A4—Rufinamide—epilepsy syndrome	0.00186	0.00431	CbGbCtD
Buprenorphine—CYP3A4—Carbamazepine—epilepsy syndrome	0.00181	0.0042	CbGbCtD
Buprenorphine—CYP3A4—Primidone—epilepsy syndrome	0.00169	0.00392	CbGbCtD
Buprenorphine—CYP3A4—Phenytoin—epilepsy syndrome	0.00162	0.00377	CbGbCtD
Buprenorphine—CYP3A4—Propofol—epilepsy syndrome	0.00151	0.00351	CbGbCtD
Buprenorphine—CYP3A4—Phenobarbital—epilepsy syndrome	0.00145	0.00336	CbGbCtD
Buprenorphine—CYP3A4—Acetazolamide—epilepsy syndrome	0.00145	0.00336	CbGbCtD
Buprenorphine—CYP3A4—Midazolam—epilepsy syndrome	0.00143	0.00331	CbGbCtD
Buprenorphine—OPRM1—telencephalic ventricle—epilepsy syndrome	0.00141	0.0741	CbGeAlD
Buprenorphine—CYP3A4—Diazepam—epilepsy syndrome	0.00137	0.00318	CbGbCtD
Buprenorphine—CYP3A4—Zonisamide—epilepsy syndrome	0.00134	0.00311	CbGbCtD
Buprenorphine—OPRD1—ganglion—epilepsy syndrome	0.00129	0.0676	CbGeAlD
Buprenorphine—OPRL1—brainstem—epilepsy syndrome	0.00109	0.057	CbGeAlD
Buprenorphine—CYP3A4—Valproic Acid—epilepsy syndrome	0.00108	0.00251	CbGbCtD
Buprenorphine—OPRL1—forebrain—epilepsy syndrome	0.00105	0.055	CbGeAlD
Buprenorphine—CYP3A4—Topiramate—epilepsy syndrome	0.000976	0.00226	CbGbCtD
Buprenorphine—OPRL1—telencephalon—epilepsy syndrome	0.000965	0.0506	CbGeAlD
Buprenorphine—OPRM1—ganglion—epilepsy syndrome	0.000879	0.0461	CbGeAlD
Buprenorphine—OPRL1—spinal cord—epilepsy syndrome	0.000676	0.0355	CbGeAlD
Buprenorphine—OPRL1—head—epilepsy syndrome	0.000601	0.0315	CbGeAlD
Buprenorphine—OPRL1—nervous system—epilepsy syndrome	0.00057	0.0299	CbGeAlD
Buprenorphine—OPRL1—central nervous system—epilepsy syndrome	0.000549	0.0288	CbGeAlD
Buprenorphine—OPRD1—forebrain—epilepsy syndrome	0.000541	0.0284	CbGeAlD
Buprenorphine—OPRK1—forebrain—epilepsy syndrome	0.000519	0.0272	CbGeAlD
Buprenorphine—OPRD1—telencephalon—epilepsy syndrome	0.000497	0.0261	CbGeAlD
Buprenorphine—OPRL1—brain—epilepsy syndrome	0.000436	0.0228	CbGeAlD
Buprenorphine—OPRM1—brainstem—epilepsy syndrome	0.000382	0.02	CbGeAlD
Buprenorphine—OPRM1—forebrain—epilepsy syndrome	0.000369	0.0193	CbGeAlD
Buprenorphine—Butorphanol—OPRD1—epilepsy syndrome	0.000355	0.108	CrCbGaD
Buprenorphine—OPRM1—telencephalon—epilepsy syndrome	0.000339	0.0178	CbGeAlD
Buprenorphine—Nalbuphine—OPRD1—epilepsy syndrome	0.000325	0.0983	CrCbGaD
Buprenorphine—OPRD1—head—epilepsy syndrome	0.00031	0.0162	CbGeAlD
Buprenorphine—OPRK1—head—epilepsy syndrome	0.000297	0.0156	CbGeAlD
Buprenorphine—OPRD1—nervous system—epilepsy syndrome	0.000294	0.0154	CbGeAlD
Buprenorphine—OPRD1—central nervous system—epilepsy syndrome	0.000283	0.0148	CbGeAlD
Buprenorphine—OPRK1—nervous system—epilepsy syndrome	0.000282	0.0148	CbGeAlD
Buprenorphine—Methylnaltrexone—OPRM1—epilepsy syndrome	0.000272	0.0823	CrCbGaD
Buprenorphine—Butorphanol—OPRM1—epilepsy syndrome	0.000272	0.0823	CrCbGaD
Buprenorphine—OPRK1—central nervous system—epilepsy syndrome	0.000271	0.0142	CbGeAlD
Buprenorphine—CYP2D6—hindbrain—epilepsy syndrome	0.000267	0.014	CbGeAlD
Buprenorphine—OPRK1—cerebellum—epilepsy syndrome	0.000265	0.0139	CbGeAlD
Buprenorphine—Oxymorphone—OPRD1—epilepsy syndrome	0.000265	0.0802	CrCbGaD
Buprenorphine—Naltrexone—OPRD1—epilepsy syndrome	0.000265	0.0802	CrCbGaD
Buprenorphine—Nalbuphine—OPRM1—epilepsy syndrome	0.000249	0.0752	CrCbGaD
Buprenorphine—OPRM1—midbrain—epilepsy syndrome	0.000244	0.0128	CbGeAlD
Buprenorphine—OPRM1—spinal cord—epilepsy syndrome	0.000238	0.0125	CbGeAlD
Buprenorphine—Naloxone—SLCO1A2—epilepsy syndrome	0.000232	0.0703	CrCbGaD
Buprenorphine—OPRD1—brain—epilepsy syndrome	0.000224	0.0118	CbGeAlD
Buprenorphine—OPRK1—brain—epilepsy syndrome	0.000215	0.0113	CbGeAlD
Buprenorphine—OPRM1—head—epilepsy syndrome	0.000211	0.0111	CbGeAlD
Buprenorphine—Naltrexone—OPRM1—epilepsy syndrome	0.000203	0.0613	CrCbGaD
Buprenorphine—Oxymorphone—OPRM1—epilepsy syndrome	0.000203	0.0613	CrCbGaD
Buprenorphine—CYP2A6—cerebellum—epilepsy syndrome	0.000202	0.0106	CbGeAlD
Buprenorphine—OPRM1—nervous system—epilepsy syndrome	0.0002	0.0105	CbGeAlD
Buprenorphine—ABCG2—telencephalon—epilepsy syndrome	0.000198	0.0104	CbGeAlD
Buprenorphine—Naloxone—OPRD1—epilepsy syndrome	0.000193	0.0585	CrCbGaD
Buprenorphine—OPRM1—central nervous system—epilepsy syndrome	0.000193	0.0101	CbGeAlD
Buprenorphine—CYP2A6—brain—epilepsy syndrome	0.000164	0.0086	CbGeAlD
Buprenorphine—ABCG2—medulla oblongata—epilepsy syndrome	0.000156	0.00817	CbGeAlD
Buprenorphine—CYP2D6—brainstem—epilepsy syndrome	0.000153	0.00803	CbGeAlD
Buprenorphine—OPRM1—brain—epilepsy syndrome	0.000153	0.00803	CbGeAlD
Buprenorphine—CYP2D6—forebrain—epilepsy syndrome	0.000148	0.00775	CbGeAlD
Buprenorphine—Naloxone—OPRM1—epilepsy syndrome	0.000148	0.0447	CrCbGaD
Buprenorphine—ABCG2—midbrain—epilepsy syndrome	0.000142	0.00747	CbGeAlD
Buprenorphine—ABCG2—spinal cord—epilepsy syndrome	0.000139	0.00729	CbGeAlD
Buprenorphine—CYP2D6—telencephalon—epilepsy syndrome	0.000136	0.00713	CbGeAlD
Buprenorphine—ABCG2—cerebellum—epilepsy syndrome	0.00011	0.00578	CbGeAlD
Buprenorphine—ABCB1—forebrain—epilepsy syndrome	0.000106	0.00558	CbGeAlD
Buprenorphine—Methylnaltrexone—CYP2D6—epilepsy syndrome	0.000105	0.0319	CrCbGaD
Buprenorphine—ABCB1—telencephalon—epilepsy syndrome	9.78e-05	0.00513	CbGeAlD
Buprenorphine—CYP2C8—brain—epilepsy syndrome	9.21e-05	0.00483	CbGeAlD
Buprenorphine—ABCG2—brain—epilepsy syndrome	8.95e-05	0.00469	CbGeAlD
Buprenorphine—CYP2D6—head—epilepsy syndrome	8.47e-05	0.00444	CbGeAlD
Buprenorphine—CYP3A4—nervous system—epilepsy syndrome	8.16e-05	0.00428	CbGeAlD
Buprenorphine—CYP2D6—nervous system—epilepsy syndrome	8.03e-05	0.00421	CbGeAlD
Buprenorphine—CYP3A4—central nervous system—epilepsy syndrome	7.85e-05	0.00412	CbGeAlD
Buprenorphine—Oxymorphone—CYP2D6—epilepsy syndrome	7.84e-05	0.0237	CrCbGaD
Buprenorphine—CYP2D6—central nervous system—epilepsy syndrome	7.73e-05	0.00405	CbGeAlD
Buprenorphine—ABCB1—medulla oblongata—epilepsy syndrome	7.69e-05	0.00403	CbGeAlD
Buprenorphine—CYP2D6—cerebellum—epilepsy syndrome	7.56e-05	0.00396	CbGeAlD
Buprenorphine—ABCB1—midbrain—epilepsy syndrome	7.03e-05	0.00368	CbGeAlD
Buprenorphine—ABCB1—spinal cord—epilepsy syndrome	6.85e-05	0.00359	CbGeAlD
Buprenorphine—CYP2D6—brain—epilepsy syndrome	6.14e-05	0.00322	CbGeAlD
Buprenorphine—ABCB1—head—epilepsy syndrome	6.09e-05	0.00319	CbGeAlD
Buprenorphine—ABCB1—nervous system—epilepsy syndrome	5.78e-05	0.00303	CbGeAlD
Buprenorphine—Naltrexone—ABCB1—epilepsy syndrome	5.6e-05	0.017	CrCbGaD
Buprenorphine—ABCB1—central nervous system—epilepsy syndrome	5.56e-05	0.00292	CbGeAlD
Buprenorphine—ABCB1—cerebellum—epilepsy syndrome	5.43e-05	0.00285	CbGeAlD
Buprenorphine—ABCB1—brain—epilepsy syndrome	4.41e-05	0.00231	CbGeAlD
Buprenorphine—Naloxone—ALB—epilepsy syndrome	4.28e-05	0.013	CrCbGaD
Buprenorphine—Naloxone—ABCB1—epilepsy syndrome	4.09e-05	0.0124	CrCbGaD
Buprenorphine—Chest pain—Pregabalin—epilepsy syndrome	2.39e-05	0.000163	CcSEcCtD
Buprenorphine—Ill-defined disorder—Gabapentin—epilepsy syndrome	2.39e-05	0.000163	CcSEcCtD
Buprenorphine—Dizziness—Zonisamide—epilepsy syndrome	2.39e-05	0.000163	CcSEcCtD
Buprenorphine—Headache—Diazepam—epilepsy syndrome	2.39e-05	0.000163	CcSEcCtD
Buprenorphine—Anxiety—Pregabalin—epilepsy syndrome	2.39e-05	0.000163	CcSEcCtD
Buprenorphine—Diarrhoea—Clonazepam—epilepsy syndrome	2.39e-05	0.000162	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.38e-05	0.000162	CcSEcCtD
Buprenorphine—Hypotension—Valproic Acid—epilepsy syndrome	2.37e-05	0.000162	CcSEcCtD
Buprenorphine—Asthenia—Carbamazepine—epilepsy syndrome	2.37e-05	0.000162	CcSEcCtD
Buprenorphine—Agitation—Gabapentin—epilepsy syndrome	2.37e-05	0.000161	CcSEcCtD
Buprenorphine—Diarrhoea—Phenytoin—epilepsy syndrome	2.37e-05	0.000161	CcSEcCtD
Buprenorphine—Discomfort—Pregabalin—epilepsy syndrome	2.37e-05	0.000161	CcSEcCtD
Buprenorphine—Nausea—Fosphenytoin—epilepsy syndrome	2.36e-05	0.000161	CcSEcCtD
Buprenorphine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.36e-05	0.000161	CcSEcCtD
Buprenorphine—Angioedema—Gabapentin—epilepsy syndrome	2.36e-05	0.000161	CcSEcCtD
Buprenorphine—Hypersensitivity—Lamotrigine—epilepsy syndrome	2.35e-05	0.00016	CcSEcCtD
Buprenorphine—Vomiting—Felbamate—epilepsy syndrome	2.35e-05	0.00016	CcSEcCtD
Buprenorphine—Dry mouth—Pregabalin—epilepsy syndrome	2.34e-05	0.00016	CcSEcCtD
Buprenorphine—Pruritus—Carbamazepine—epilepsy syndrome	2.34e-05	0.000159	CcSEcCtD
Buprenorphine—Rash—Felbamate—epilepsy syndrome	2.33e-05	0.000159	CcSEcCtD
Buprenorphine—Eye disorder—Topiramate—epilepsy syndrome	2.33e-05	0.000159	CcSEcCtD
Buprenorphine—Dermatitis—Felbamate—epilepsy syndrome	2.33e-05	0.000159	CcSEcCtD
Buprenorphine—Malaise—Gabapentin—epilepsy syndrome	2.33e-05	0.000158	CcSEcCtD
Buprenorphine—Tinnitus—Topiramate—epilepsy syndrome	2.32e-05	0.000158	CcSEcCtD
Buprenorphine—Vertigo—Gabapentin—epilepsy syndrome	2.32e-05	0.000158	CcSEcCtD
Buprenorphine—Headache—Felbamate—epilepsy syndrome	2.31e-05	0.000158	CcSEcCtD
Buprenorphine—Confusional state—Pregabalin—epilepsy syndrome	2.31e-05	0.000158	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.31e-05	0.000158	CcSEcCtD
Buprenorphine—Flushing—Topiramate—epilepsy syndrome	2.31e-05	0.000158	CcSEcCtD
Buprenorphine—Cardiac disorder—Topiramate—epilepsy syndrome	2.31e-05	0.000158	CcSEcCtD
Buprenorphine—Syncope—Gabapentin—epilepsy syndrome	2.31e-05	0.000158	CcSEcCtD
Buprenorphine—Dizziness—Clonazepam—epilepsy syndrome	2.31e-05	0.000157	CcSEcCtD
Buprenorphine—Nausea—Vigabatrin—epilepsy syndrome	2.3e-05	0.000157	CcSEcCtD
Buprenorphine—Vomiting—Zonisamide—epilepsy syndrome	2.3e-05	0.000157	CcSEcCtD
Buprenorphine—Insomnia—Valproic Acid—epilepsy syndrome	2.3e-05	0.000156	CcSEcCtD
Buprenorphine—Oedema—Pregabalin—epilepsy syndrome	2.29e-05	0.000156	CcSEcCtD
Buprenorphine—Anaphylactic shock—Pregabalin—epilepsy syndrome	2.29e-05	0.000156	CcSEcCtD
Buprenorphine—Asthenia—Lamotrigine—epilepsy syndrome	2.29e-05	0.000156	CcSEcCtD
Buprenorphine—Dizziness—Phenytoin—epilepsy syndrome	2.29e-05	0.000156	CcSEcCtD
Buprenorphine—Rash—Zonisamide—epilepsy syndrome	2.28e-05	0.000155	CcSEcCtD
Buprenorphine—Infection—Pregabalin—epilepsy syndrome	2.28e-05	0.000155	CcSEcCtD
Buprenorphine—Paraesthesia—Valproic Acid—epilepsy syndrome	2.28e-05	0.000155	CcSEcCtD
Buprenorphine—Palpitations—Gabapentin—epilepsy syndrome	2.28e-05	0.000155	CcSEcCtD
Buprenorphine—Dermatitis—Zonisamide—epilepsy syndrome	2.28e-05	0.000155	CcSEcCtD
Buprenorphine—Dizziness—Oxcarbazepine—epilepsy syndrome	2.28e-05	0.000155	CcSEcCtD
Buprenorphine—Nausea—Diazepam—epilepsy syndrome	2.27e-05	0.000155	CcSEcCtD
Buprenorphine—Loss of consciousness—Gabapentin—epilepsy syndrome	2.27e-05	0.000154	CcSEcCtD
Buprenorphine—Headache—Zonisamide—epilepsy syndrome	2.27e-05	0.000154	CcSEcCtD
Buprenorphine—Dyspnoea—Valproic Acid—epilepsy syndrome	2.26e-05	0.000154	CcSEcCtD
Buprenorphine—Diarrhoea—Carbamazepine—epilepsy syndrome	2.26e-05	0.000154	CcSEcCtD
Buprenorphine—Angiopathy—Topiramate—epilepsy syndrome	2.26e-05	0.000154	CcSEcCtD
Buprenorphine—Pruritus—Lamotrigine—epilepsy syndrome	2.26e-05	0.000154	CcSEcCtD
Buprenorphine—Shock—Pregabalin—epilepsy syndrome	2.26e-05	0.000154	CcSEcCtD
Buprenorphine—Somnolence—Valproic Acid—epilepsy syndrome	2.26e-05	0.000154	CcSEcCtD
Buprenorphine—Immune system disorder—Topiramate—epilepsy syndrome	2.25e-05	0.000153	CcSEcCtD
Buprenorphine—Nervous system disorder—Pregabalin—epilepsy syndrome	2.25e-05	0.000153	CcSEcCtD
Buprenorphine—Cough—Gabapentin—epilepsy syndrome	2.25e-05	0.000153	CcSEcCtD
Buprenorphine—Mediastinal disorder—Topiramate—epilepsy syndrome	2.25e-05	0.000153	CcSEcCtD
Buprenorphine—Tachycardia—Pregabalin—epilepsy syndrome	2.24e-05	0.000153	CcSEcCtD
Buprenorphine—Chills—Topiramate—epilepsy syndrome	2.24e-05	0.000152	CcSEcCtD
Buprenorphine—Dyspepsia—Valproic Acid—epilepsy syndrome	2.23e-05	0.000152	CcSEcCtD
Buprenorphine—Convulsion—Gabapentin—epilepsy syndrome	2.23e-05	0.000152	CcSEcCtD
Buprenorphine—Skin disorder—Pregabalin—epilepsy syndrome	2.23e-05	0.000152	CcSEcCtD
Buprenorphine—Hypertension—Gabapentin—epilepsy syndrome	2.23e-05	0.000152	CcSEcCtD
Buprenorphine—Hyperhidrosis—Pregabalin—epilepsy syndrome	2.22e-05	0.000151	CcSEcCtD
Buprenorphine—Vomiting—Clonazepam—epilepsy syndrome	2.22e-05	0.000151	CcSEcCtD
Buprenorphine—Decreased appetite—Valproic Acid—epilepsy syndrome	2.21e-05	0.00015	CcSEcCtD
Buprenorphine—Vomiting—Phenytoin—epilepsy syndrome	2.2e-05	0.00015	CcSEcCtD
Buprenorphine—Rash—Clonazepam—epilepsy syndrome	2.2e-05	0.00015	CcSEcCtD
Buprenorphine—Dermatitis—Clonazepam—epilepsy syndrome	2.2e-05	0.00015	CcSEcCtD
Buprenorphine—Chest pain—Gabapentin—epilepsy syndrome	2.2e-05	0.00015	CcSEcCtD
Buprenorphine—Myalgia—Gabapentin—epilepsy syndrome	2.2e-05	0.00015	CcSEcCtD
Buprenorphine—Arthralgia—Gabapentin—epilepsy syndrome	2.2e-05	0.00015	CcSEcCtD
Buprenorphine—Nausea—Felbamate—epilepsy syndrome	2.19e-05	0.00015	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	2.19e-05	0.000149	CcSEcCtD
Buprenorphine—Vomiting—Oxcarbazepine—epilepsy syndrome	2.19e-05	0.000149	CcSEcCtD
Buprenorphine—Fatigue—Valproic Acid—epilepsy syndrome	2.19e-05	0.000149	CcSEcCtD
Buprenorphine—Anxiety—Gabapentin—epilepsy syndrome	2.19e-05	0.000149	CcSEcCtD
Buprenorphine—Anorexia—Pregabalin—epilepsy syndrome	2.19e-05	0.000149	CcSEcCtD
Buprenorphine—Dizziness—Carbamazepine—epilepsy syndrome	2.19e-05	0.000149	CcSEcCtD
Buprenorphine—Diarrhoea—Lamotrigine—epilepsy syndrome	2.19e-05	0.000149	CcSEcCtD
Buprenorphine—Headache—Clonazepam—epilepsy syndrome	2.18e-05	0.000149	CcSEcCtD
Buprenorphine—Rash—Phenytoin—epilepsy syndrome	2.18e-05	0.000149	CcSEcCtD
Buprenorphine—Mental disorder—Topiramate—epilepsy syndrome	2.18e-05	0.000149	CcSEcCtD
Buprenorphine—Dermatitis—Phenytoin—epilepsy syndrome	2.18e-05	0.000149	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	2.18e-05	0.000149	CcSEcCtD
Buprenorphine—Rash—Oxcarbazepine—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Constipation—Valproic Acid—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Pain—Valproic Acid—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Dermatitis—Oxcarbazepine—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Headache—Phenytoin—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Malnutrition—Topiramate—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Erythema—Topiramate—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Discomfort—Gabapentin—epilepsy syndrome	2.17e-05	0.000148	CcSEcCtD
Buprenorphine—Headache—Oxcarbazepine—epilepsy syndrome	2.16e-05	0.000147	CcSEcCtD
Buprenorphine—Nausea—Zonisamide—epilepsy syndrome	2.15e-05	0.000146	CcSEcCtD
Buprenorphine—Dry mouth—Gabapentin—epilepsy syndrome	2.15e-05	0.000146	CcSEcCtD
Buprenorphine—Hypotension—Pregabalin—epilepsy syndrome	2.14e-05	0.000146	CcSEcCtD
Buprenorphine—Flatulence—Topiramate—epilepsy syndrome	2.14e-05	0.000146	CcSEcCtD
Buprenorphine—Tension—Topiramate—epilepsy syndrome	2.13e-05	0.000145	CcSEcCtD
Buprenorphine—Dysgeusia—Topiramate—epilepsy syndrome	2.12e-05	0.000145	CcSEcCtD
Buprenorphine—Confusional state—Gabapentin—epilepsy syndrome	2.12e-05	0.000145	CcSEcCtD
Buprenorphine—Dizziness—Lamotrigine—epilepsy syndrome	2.11e-05	0.000144	CcSEcCtD
Buprenorphine—Nervousness—Topiramate—epilepsy syndrome	2.11e-05	0.000144	CcSEcCtD
Buprenorphine—Anaphylactic shock—Gabapentin—epilepsy syndrome	2.1e-05	0.000143	CcSEcCtD
Buprenorphine—Oedema—Gabapentin—epilepsy syndrome	2.1e-05	0.000143	CcSEcCtD
Buprenorphine—Vomiting—Carbamazepine—epilepsy syndrome	2.1e-05	0.000143	CcSEcCtD
Buprenorphine—Back pain—Topiramate—epilepsy syndrome	2.1e-05	0.000143	CcSEcCtD
Buprenorphine—Feeling abnormal—Valproic Acid—epilepsy syndrome	2.09e-05	0.000143	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	2.09e-05	0.000142	CcSEcCtD
Buprenorphine—Infection—Gabapentin—epilepsy syndrome	2.09e-05	0.000142	CcSEcCtD
Buprenorphine—Muscle spasms—Topiramate—epilepsy syndrome	2.09e-05	0.000142	CcSEcCtD
Buprenorphine—Rash—Carbamazepine—epilepsy syndrome	2.08e-05	0.000142	CcSEcCtD
Buprenorphine—Dermatitis—Carbamazepine—epilepsy syndrome	2.08e-05	0.000142	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	2.08e-05	0.000141	CcSEcCtD
Buprenorphine—Insomnia—Pregabalin—epilepsy syndrome	2.08e-05	0.000141	CcSEcCtD
Buprenorphine—Nausea—Clonazepam—epilepsy syndrome	2.07e-05	0.000141	CcSEcCtD
Buprenorphine—Headache—Carbamazepine—epilepsy syndrome	2.07e-05	0.000141	CcSEcCtD
Buprenorphine—Shock—Gabapentin—epilepsy syndrome	2.07e-05	0.000141	CcSEcCtD
Buprenorphine—Nervous system disorder—Gabapentin—epilepsy syndrome	2.06e-05	0.000141	CcSEcCtD
Buprenorphine—Paraesthesia—Pregabalin—epilepsy syndrome	2.06e-05	0.00014	CcSEcCtD
Buprenorphine—Nausea—Phenytoin—epilepsy syndrome	2.06e-05	0.00014	CcSEcCtD
Buprenorphine—Tachycardia—Gabapentin—epilepsy syndrome	2.05e-05	0.00014	CcSEcCtD
Buprenorphine—Dyspnoea—Pregabalin—epilepsy syndrome	2.05e-05	0.000139	CcSEcCtD
Buprenorphine—Nausea—Oxcarbazepine—epilepsy syndrome	2.05e-05	0.000139	CcSEcCtD
Buprenorphine—Vision blurred—Topiramate—epilepsy syndrome	2.04e-05	0.000139	CcSEcCtD
Buprenorphine—Skin disorder—Gabapentin—epilepsy syndrome	2.04e-05	0.000139	CcSEcCtD
Buprenorphine—Somnolence—Pregabalin—epilepsy syndrome	2.04e-05	0.000139	CcSEcCtD
Buprenorphine—Hyperhidrosis—Gabapentin—epilepsy syndrome	2.03e-05	0.000139	CcSEcCtD
Buprenorphine—Tremor—Topiramate—epilepsy syndrome	2.03e-05	0.000138	CcSEcCtD
Buprenorphine—Vomiting—Lamotrigine—epilepsy syndrome	2.03e-05	0.000138	CcSEcCtD
Buprenorphine—Urticaria—Valproic Acid—epilepsy syndrome	2.02e-05	0.000137	CcSEcCtD
Buprenorphine—Rash—Lamotrigine—epilepsy syndrome	2.01e-05	0.000137	CcSEcCtD
Buprenorphine—Ill-defined disorder—Topiramate—epilepsy syndrome	2.01e-05	0.000137	CcSEcCtD
Buprenorphine—Dermatitis—Lamotrigine—epilepsy syndrome	2.01e-05	0.000137	CcSEcCtD
Buprenorphine—Abdominal pain—Valproic Acid—epilepsy syndrome	2.01e-05	0.000137	CcSEcCtD
Buprenorphine—Body temperature increased—Valproic Acid—epilepsy syndrome	2.01e-05	0.000137	CcSEcCtD
Buprenorphine—Anorexia—Gabapentin—epilepsy syndrome	2.01e-05	0.000137	CcSEcCtD
Buprenorphine—Headache—Lamotrigine—epilepsy syndrome	2e-05	0.000136	CcSEcCtD
Buprenorphine—Decreased appetite—Pregabalin—epilepsy syndrome	1.99e-05	0.000136	CcSEcCtD
Buprenorphine—Agitation—Topiramate—epilepsy syndrome	1.99e-05	0.000136	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.98e-05	0.000135	CcSEcCtD
Buprenorphine—Fatigue—Pregabalin—epilepsy syndrome	1.98e-05	0.000135	CcSEcCtD
Buprenorphine—Hypotension—Gabapentin—epilepsy syndrome	1.97e-05	0.000134	CcSEcCtD
Buprenorphine—Nausea—Carbamazepine—epilepsy syndrome	1.96e-05	0.000134	CcSEcCtD
Buprenorphine—Constipation—Pregabalin—epilepsy syndrome	1.96e-05	0.000134	CcSEcCtD
Buprenorphine—Pain—Pregabalin—epilepsy syndrome	1.96e-05	0.000134	CcSEcCtD
Buprenorphine—Malaise—Topiramate—epilepsy syndrome	1.96e-05	0.000133	CcSEcCtD
Buprenorphine—Vertigo—Topiramate—epilepsy syndrome	1.95e-05	0.000133	CcSEcCtD
Buprenorphine—Syncope—Topiramate—epilepsy syndrome	1.95e-05	0.000133	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.92e-05	0.000131	CcSEcCtD
Buprenorphine—Palpitations—Topiramate—epilepsy syndrome	1.92e-05	0.000131	CcSEcCtD
Buprenorphine—Loss of consciousness—Topiramate—epilepsy syndrome	1.91e-05	0.00013	CcSEcCtD
Buprenorphine—Insomnia—Gabapentin—epilepsy syndrome	1.9e-05	0.00013	CcSEcCtD
Buprenorphine—Nausea—Lamotrigine—epilepsy syndrome	1.9e-05	0.000129	CcSEcCtD
Buprenorphine—Cough—Topiramate—epilepsy syndrome	1.89e-05	0.000129	CcSEcCtD
Buprenorphine—Feeling abnormal—Pregabalin—epilepsy syndrome	1.89e-05	0.000129	CcSEcCtD
Buprenorphine—Paraesthesia—Gabapentin—epilepsy syndrome	1.89e-05	0.000129	CcSEcCtD
Buprenorphine—Convulsion—Topiramate—epilepsy syndrome	1.88e-05	0.000128	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.88e-05	0.000128	CcSEcCtD
Buprenorphine—Dyspnoea—Gabapentin—epilepsy syndrome	1.88e-05	0.000128	CcSEcCtD
Buprenorphine—Hypertension—Topiramate—epilepsy syndrome	1.87e-05	0.000128	CcSEcCtD
Buprenorphine—Somnolence—Gabapentin—epilepsy syndrome	1.87e-05	0.000127	CcSEcCtD
Buprenorphine—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.87e-05	0.000127	CcSEcCtD
Buprenorphine—Dyspepsia—Gabapentin—epilepsy syndrome	1.85e-05	0.000126	CcSEcCtD
Buprenorphine—Arthralgia—Topiramate—epilepsy syndrome	1.85e-05	0.000126	CcSEcCtD
Buprenorphine—Chest pain—Topiramate—epilepsy syndrome	1.85e-05	0.000126	CcSEcCtD
Buprenorphine—Myalgia—Topiramate—epilepsy syndrome	1.85e-05	0.000126	CcSEcCtD
Buprenorphine—Anxiety—Topiramate—epilepsy syndrome	1.84e-05	0.000125	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.83e-05	0.000125	CcSEcCtD
Buprenorphine—Decreased appetite—Gabapentin—epilepsy syndrome	1.83e-05	0.000125	CcSEcCtD
Buprenorphine—Discomfort—Topiramate—epilepsy syndrome	1.82e-05	0.000124	CcSEcCtD
Buprenorphine—Urticaria—Pregabalin—epilepsy syndrome	1.82e-05	0.000124	CcSEcCtD
Buprenorphine—Asthenia—Valproic Acid—epilepsy syndrome	1.82e-05	0.000124	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.82e-05	0.000124	CcSEcCtD
Buprenorphine—Fatigue—Gabapentin—epilepsy syndrome	1.81e-05	0.000124	CcSEcCtD
Buprenorphine—Body temperature increased—Pregabalin—epilepsy syndrome	1.81e-05	0.000124	CcSEcCtD
Buprenorphine—Abdominal pain—Pregabalin—epilepsy syndrome	1.81e-05	0.000124	CcSEcCtD
Buprenorphine—Dry mouth—Topiramate—epilepsy syndrome	1.81e-05	0.000123	CcSEcCtD
Buprenorphine—Constipation—Gabapentin—epilepsy syndrome	1.8e-05	0.000123	CcSEcCtD
Buprenorphine—Pain—Gabapentin—epilepsy syndrome	1.8e-05	0.000123	CcSEcCtD
Buprenorphine—Pruritus—Valproic Acid—epilepsy syndrome	1.8e-05	0.000122	CcSEcCtD
Buprenorphine—Confusional state—Topiramate—epilepsy syndrome	1.79e-05	0.000122	CcSEcCtD
Buprenorphine—Oedema—Topiramate—epilepsy syndrome	1.77e-05	0.000121	CcSEcCtD
Buprenorphine—Infection—Topiramate—epilepsy syndrome	1.76e-05	0.00012	CcSEcCtD
Buprenorphine—Shock—Topiramate—epilepsy syndrome	1.74e-05	0.000119	CcSEcCtD
Buprenorphine—Diarrhoea—Valproic Acid—epilepsy syndrome	1.74e-05	0.000118	CcSEcCtD
Buprenorphine—Nervous system disorder—Topiramate—epilepsy syndrome	1.74e-05	0.000118	CcSEcCtD
Buprenorphine—Feeling abnormal—Gabapentin—epilepsy syndrome	1.73e-05	0.000118	CcSEcCtD
Buprenorphine—Tachycardia—Topiramate—epilepsy syndrome	1.73e-05	0.000118	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.72e-05	0.000117	CcSEcCtD
Buprenorphine—Skin disorder—Topiramate—epilepsy syndrome	1.72e-05	0.000117	CcSEcCtD
Buprenorphine—Hyperhidrosis—Topiramate—epilepsy syndrome	1.71e-05	0.000117	CcSEcCtD
Buprenorphine—Hypersensitivity—Pregabalin—epilepsy syndrome	1.69e-05	0.000115	CcSEcCtD
Buprenorphine—Anorexia—Topiramate—epilepsy syndrome	1.69e-05	0.000115	CcSEcCtD
Buprenorphine—Dizziness—Valproic Acid—epilepsy syndrome	1.68e-05	0.000114	CcSEcCtD
Buprenorphine—Urticaria—Gabapentin—epilepsy syndrome	1.67e-05	0.000114	CcSEcCtD
Buprenorphine—Body temperature increased—Gabapentin—epilepsy syndrome	1.66e-05	0.000113	CcSEcCtD
Buprenorphine—Abdominal pain—Gabapentin—epilepsy syndrome	1.66e-05	0.000113	CcSEcCtD
Buprenorphine—Hypotension—Topiramate—epilepsy syndrome	1.65e-05	0.000113	CcSEcCtD
Buprenorphine—Asthenia—Pregabalin—epilepsy syndrome	1.65e-05	0.000112	CcSEcCtD
Buprenorphine—Pruritus—Pregabalin—epilepsy syndrome	1.62e-05	0.000111	CcSEcCtD
Buprenorphine—Vomiting—Valproic Acid—epilepsy syndrome	1.61e-05	0.00011	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.61e-05	0.00011	CcSEcCtD
Buprenorphine—Insomnia—Topiramate—epilepsy syndrome	1.6e-05	0.000109	CcSEcCtD
Buprenorphine—Rash—Valproic Acid—epilepsy syndrome	1.6e-05	0.000109	CcSEcCtD
Buprenorphine—Dermatitis—Valproic Acid—epilepsy syndrome	1.6e-05	0.000109	CcSEcCtD
Buprenorphine—Headache—Valproic Acid—epilepsy syndrome	1.59e-05	0.000108	CcSEcCtD
Buprenorphine—Paraesthesia—Topiramate—epilepsy syndrome	1.59e-05	0.000108	CcSEcCtD
Buprenorphine—Dyspnoea—Topiramate—epilepsy syndrome	1.58e-05	0.000108	CcSEcCtD
Buprenorphine—Somnolence—Topiramate—epilepsy syndrome	1.57e-05	0.000107	CcSEcCtD
Buprenorphine—Diarrhoea—Pregabalin—epilepsy syndrome	1.57e-05	0.000107	CcSEcCtD
Buprenorphine—Dyspepsia—Topiramate—epilepsy syndrome	1.56e-05	0.000106	CcSEcCtD
Buprenorphine—Hypersensitivity—Gabapentin—epilepsy syndrome	1.55e-05	0.000106	CcSEcCtD
Buprenorphine—Decreased appetite—Topiramate—epilepsy syndrome	1.54e-05	0.000105	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.53e-05	0.000104	CcSEcCtD
Buprenorphine—Fatigue—Topiramate—epilepsy syndrome	1.53e-05	0.000104	CcSEcCtD
Buprenorphine—Dizziness—Pregabalin—epilepsy syndrome	1.52e-05	0.000103	CcSEcCtD
Buprenorphine—Pain—Topiramate—epilepsy syndrome	1.51e-05	0.000103	CcSEcCtD
Buprenorphine—Constipation—Topiramate—epilepsy syndrome	1.51e-05	0.000103	CcSEcCtD
Buprenorphine—Asthenia—Gabapentin—epilepsy syndrome	1.51e-05	0.000103	CcSEcCtD
Buprenorphine—Nausea—Valproic Acid—epilepsy syndrome	1.51e-05	0.000103	CcSEcCtD
Buprenorphine—Pruritus—Gabapentin—epilepsy syndrome	1.49e-05	0.000101	CcSEcCtD
Buprenorphine—Vomiting—Pregabalin—epilepsy syndrome	1.46e-05	9.94e-05	CcSEcCtD
Buprenorphine—Feeling abnormal—Topiramate—epilepsy syndrome	1.46e-05	9.94e-05	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.45e-05	9.86e-05	CcSEcCtD
Buprenorphine—Rash—Pregabalin—epilepsy syndrome	1.45e-05	9.86e-05	CcSEcCtD
Buprenorphine—Dermatitis—Pregabalin—epilepsy syndrome	1.45e-05	9.85e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Gabapentin—epilepsy syndrome	1.44e-05	9.81e-05	CcSEcCtD
Buprenorphine—Headache—Pregabalin—epilepsy syndrome	1.44e-05	9.79e-05	CcSEcCtD
Buprenorphine—Urticaria—Topiramate—epilepsy syndrome	1.41e-05	9.58e-05	CcSEcCtD
Buprenorphine—Abdominal pain—Topiramate—epilepsy syndrome	1.4e-05	9.53e-05	CcSEcCtD
Buprenorphine—Body temperature increased—Topiramate—epilepsy syndrome	1.4e-05	9.53e-05	CcSEcCtD
Buprenorphine—Dizziness—Gabapentin—epilepsy syndrome	1.39e-05	9.48e-05	CcSEcCtD
Buprenorphine—Nausea—Pregabalin—epilepsy syndrome	1.36e-05	9.29e-05	CcSEcCtD
Buprenorphine—Vomiting—Gabapentin—epilepsy syndrome	1.34e-05	9.12e-05	CcSEcCtD
Buprenorphine—Rash—Gabapentin—epilepsy syndrome	1.33e-05	9.04e-05	CcSEcCtD
Buprenorphine—Dermatitis—Gabapentin—epilepsy syndrome	1.33e-05	9.03e-05	CcSEcCtD
Buprenorphine—Headache—Gabapentin—epilepsy syndrome	1.32e-05	8.98e-05	CcSEcCtD
Buprenorphine—Hypersensitivity—Topiramate—epilepsy syndrome	1.3e-05	8.89e-05	CcSEcCtD
Buprenorphine—Asthenia—Topiramate—epilepsy syndrome	1.27e-05	8.65e-05	CcSEcCtD
Buprenorphine—Pruritus—Topiramate—epilepsy syndrome	1.25e-05	8.53e-05	CcSEcCtD
Buprenorphine—Nausea—Gabapentin—epilepsy syndrome	1.25e-05	8.52e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Topiramate—epilepsy syndrome	1.21e-05	8.25e-05	CcSEcCtD
Buprenorphine—Dizziness—Topiramate—epilepsy syndrome	1.17e-05	7.98e-05	CcSEcCtD
Buprenorphine—Vomiting—Topiramate—epilepsy syndrome	1.13e-05	7.67e-05	CcSEcCtD
Buprenorphine—Rash—Topiramate—epilepsy syndrome	1.12e-05	7.6e-05	CcSEcCtD
Buprenorphine—Dermatitis—Topiramate—epilepsy syndrome	1.12e-05	7.6e-05	CcSEcCtD
Buprenorphine—Headache—Topiramate—epilepsy syndrome	1.11e-05	7.56e-05	CcSEcCtD
Buprenorphine—Nausea—Topiramate—epilepsy syndrome	1.05e-05	7.16e-05	CcSEcCtD
Buprenorphine—CYP2A6—Metabolism—ABCB1—epilepsy syndrome	2.21e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—SLC2A1—epilepsy syndrome	2.2e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.2e-06	3.12e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALAD—epilepsy syndrome	2.2e-06	3.12e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NT5E—epilepsy syndrome	2.2e-06	3.12e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.19e-06	3.11e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PLCB1—epilepsy syndrome	2.18e-06	3.09e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TH—epilepsy syndrome	2.17e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—POMC—epilepsy syndrome	2.17e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KDR—epilepsy syndrome	2.17e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCG2—epilepsy syndrome	2.16e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—YWHAZ—epilepsy syndrome	2.14e-06	3.03e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL2—epilepsy syndrome	2.12e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.12e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NGF—epilepsy syndrome	2.11e-06	3e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP2D6—epilepsy syndrome	2.11e-06	3e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ABCG2—epilepsy syndrome	2.1e-06	2.99e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	2.1e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	2.1e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP11A1—epilepsy syndrome	2.09e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PRKCB—epilepsy syndrome	2.09e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6ST—epilepsy syndrome	2.08e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	2.07e-06	2.94e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	2.06e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	2.06e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCR5—epilepsy syndrome	2.05e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	2.05e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GPX1—epilepsy syndrome	2.05e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	2.05e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	2.04e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AKT1—epilepsy syndrome	2.03e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADSL—epilepsy syndrome	2.01e-06	2.86e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HTR2A—epilepsy syndrome	2.01e-06	2.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ADRA2A—epilepsy syndrome	2.01e-06	2.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—BCHE—epilepsy syndrome	2e-06	2.84e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.98e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—epilepsy syndrome	1.98e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AGT—epilepsy syndrome	1.98e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.97e-06	2.8e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	1.97e-06	2.79e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—POMC—epilepsy syndrome	1.96e-06	2.79e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AGT—epilepsy syndrome	1.96e-06	2.79e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.94e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—APOE—epilepsy syndrome	1.94e-06	2.75e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.94e-06	2.75e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.93e-06	2.74e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—APOE—epilepsy syndrome	1.92e-06	2.73e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.92e-06	2.73e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.92e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—FGF2—epilepsy syndrome	1.92e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	1.92e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TSC2—epilepsy syndrome	1.91e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	1.91e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AGT—epilepsy syndrome	1.91e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	1.9e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—POMC—epilepsy syndrome	1.9e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.89e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.89e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	1.89e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	1.88e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TH—epilepsy syndrome	1.88e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.88e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APOE—epilepsy syndrome	1.87e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL2—epilepsy syndrome	1.86e-06	2.64e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.85e-06	2.63e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.84e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KDR—epilepsy syndrome	1.83e-06	2.6e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	1.81e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.81e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AGT—epilepsy syndrome	1.8e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	1.79e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ALB—epilepsy syndrome	1.79e-06	2.54e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CAT—epilepsy syndrome	1.79e-06	2.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—BCHE—epilepsy syndrome	1.79e-06	2.54e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RELA—epilepsy syndrome	1.78e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PRKCB—epilepsy syndrome	1.76e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—APOE—epilepsy syndrome	1.76e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.76e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6ST—epilepsy syndrome	1.76e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.75e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	1.75e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MTOR—epilepsy syndrome	1.74e-06	2.48e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—BCHE—epilepsy syndrome	1.74e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	1.74e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.72e-06	2.45e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	1.72e-06	2.44e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	1.7e-06	2.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	1.69e-06	2.39e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—FGF2—epilepsy syndrome	1.68e-06	2.39e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	1.68e-06	2.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TH—epilepsy syndrome	1.68e-06	2.38e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—POMC—epilepsy syndrome	1.67e-06	2.37e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	1.66e-06	2.36e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.65e-06	2.35e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—POMC—epilepsy syndrome	1.65e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.65e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PLCB1—epilepsy syndrome	1.64e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.64e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TH—epilepsy syndrome	1.64e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	1.64e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	1.64e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—BCHE—epilepsy syndrome	1.63e-06	2.31e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	1.63e-06	2.31e-05	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.62e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GPX1—epilepsy syndrome	1.62e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.61e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—POMC—epilepsy syndrome	1.61e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CASP3—epilepsy syndrome	1.6e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.59e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.59e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL2—epilepsy syndrome	1.57e-06	2.23e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	1.57e-06	2.23e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.57e-06	2.22e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—epilepsy syndrome	1.57e-06	2.22e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RELA—epilepsy syndrome	1.56e-06	2.21e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—JUN—epilepsy syndrome	1.56e-06	2.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	1.55e-06	2.21e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.55e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CAT—epilepsy syndrome	1.55e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TH—epilepsy syndrome	1.54e-06	2.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	1.54e-06	2.18e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TH—epilepsy syndrome	1.53e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MTOR—epilepsy syndrome	1.53e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ALB—epilepsy syndrome	1.52e-06	2.16e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—epilepsy syndrome	1.52e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—POMC—epilepsy syndrome	1.51e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.51e-06	2.14e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	1.51e-06	2.14e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ALB—epilepsy syndrome	1.51e-06	2.14e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.47e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—epilepsy syndrome	1.47e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	1.47e-06	2.08e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FGF2—epilepsy syndrome	1.42e-06	2.02e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.42e-06	2.02e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AGT—epilepsy syndrome	1.42e-06	2.01e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—epilepsy syndrome	1.41e-06	2e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	1.4e-06	1.99e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GPX1—epilepsy syndrome	1.4e-06	1.99e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SRC—epilepsy syndrome	1.4e-06	1.98e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	1.4e-06	1.98e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—BCHE—epilepsy syndrome	1.39e-06	1.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOE—epilepsy syndrome	1.39e-06	1.97e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CAT—epilepsy syndrome	1.38e-06	1.96e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—epilepsy syndrome	1.38e-06	1.96e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HMOX1—epilepsy syndrome	1.37e-06	1.94e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—JUN—epilepsy syndrome	1.37e-06	1.94e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—epilepsy syndrome	1.36e-06	1.93e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAT—epilepsy syndrome	1.35e-06	1.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	1.35e-06	1.91e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—epilepsy syndrome	1.33e-06	1.89e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—epilepsy syndrome	1.33e-06	1.89e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	1.33e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RELA—epilepsy syndrome	1.32e-06	1.87e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—epilepsy syndrome	1.32e-06	1.87e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	1.31e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TH—epilepsy syndrome	1.31e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	1.3e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MTOR—epilepsy syndrome	1.29e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—epilepsy syndrome	1.29e-06	1.83e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.29e-06	1.83e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.29e-06	1.83e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	1.28e-06	1.81e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.27e-06	1.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	1.26e-06	1.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAT—epilepsy syndrome	1.26e-06	1.79e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	1.26e-06	1.78e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GPX1—epilepsy syndrome	1.25e-06	1.78e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.24e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AGT—epilepsy syndrome	1.23e-06	1.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	1.23e-06	1.74e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—epilepsy syndrome	1.23e-06	1.74e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GPX1—epilepsy syndrome	1.22e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—epilepsy syndrome	1.21e-06	1.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOE—epilepsy syndrome	1.2e-06	1.71e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.2e-06	1.7e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—POMC—epilepsy syndrome	1.19e-06	1.7e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—epilepsy syndrome	1.19e-06	1.69e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—epilepsy syndrome	1.19e-06	1.69e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JUN—epilepsy syndrome	1.15e-06	1.64e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.15e-06	1.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GPX1—epilepsy syndrome	1.14e-06	1.62e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.13e-06	1.61e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—epilepsy syndrome	1.12e-06	1.6e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AGT—epilepsy syndrome	1.1e-06	1.56e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.09e-06	1.55e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—epilepsy syndrome	1.09e-06	1.55e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—epilepsy syndrome	1.09e-06	1.55e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.08e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAT—epilepsy syndrome	1.08e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOE—epilepsy syndrome	1.07e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.07e-06	1.52e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AGT—epilepsy syndrome	1.07e-06	1.52e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOE—epilepsy syndrome	1.05e-06	1.49e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	1.05e-06	1.49e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—epilepsy syndrome	1.04e-06	1.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—POMC—epilepsy syndrome	1.03e-06	1.47e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	1.02e-06	1.45e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	1.01e-06	1.44e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TH—epilepsy syndrome	1.01e-06	1.43e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—epilepsy syndrome	1.01e-06	1.43e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AGT—epilepsy syndrome	1.01e-06	1.43e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AGT—epilepsy syndrome	1e-06	1.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—epilepsy syndrome	9.96e-07	1.41e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOE—epilepsy syndrome	9.88e-07	1.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOE—epilepsy syndrome	9.8e-07	1.39e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GPX1—epilepsy syndrome	9.74e-07	1.38e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	9.52e-07	1.35e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—epilepsy syndrome	9.43e-07	1.34e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—POMC—epilepsy syndrome	9.23e-07	1.31e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—POMC—epilepsy syndrome	9.01e-07	1.28e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—epilepsy syndrome	8.69e-07	1.23e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AGT—epilepsy syndrome	8.54e-07	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—POMC—epilepsy syndrome	8.49e-07	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	8.43e-07	1.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—POMC—epilepsy syndrome	8.42e-07	1.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—epilepsy syndrome	8.41e-07	1.19e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOE—epilepsy syndrome	8.37e-07	1.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAT—epilepsy syndrome	8.31e-07	1.18e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	8.25e-07	1.17e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—epilepsy syndrome	8.21e-07	1.17e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	8.09e-07	1.15e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—epilepsy syndrome	7.87e-07	1.12e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—epilepsy syndrome	7.74e-07	1.1e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—epilepsy syndrome	7.67e-07	1.09e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—epilepsy syndrome	7.62e-07	1.08e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GPX1—epilepsy syndrome	7.52e-07	1.07e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	7.36e-07	1.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—POMC—epilepsy syndrome	7.19e-07	1.02e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—epilepsy syndrome	7.19e-07	1.02e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	6.77e-07	9.61e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	6.71e-07	9.53e-06	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—epilepsy syndrome	6.68e-07	9.48e-06	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—epilepsy syndrome	6.62e-07	9.4e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AGT—epilepsy syndrome	6.59e-07	9.36e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—epilepsy syndrome	6.56e-07	9.31e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOE—epilepsy syndrome	6.46e-07	9.17e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—epilepsy syndrome	6.44e-07	9.14e-06	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—epilepsy syndrome	6.07e-07	8.62e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	5.74e-07	8.14e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—POMC—epilepsy syndrome	5.55e-07	7.88e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—epilepsy syndrome	5.06e-07	7.18e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—epilepsy syndrome	4.79e-07	6.8e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	4.43e-07	6.29e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—epilepsy syndrome	4.15e-07	5.89e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—epilepsy syndrome	3.7e-07	5.25e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—epilepsy syndrome	3.61e-07	5.13e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—epilepsy syndrome	3.4e-07	4.83e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—epilepsy syndrome	3.37e-07	4.79e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—epilepsy syndrome	2.88e-07	4.09e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—epilepsy syndrome	2.22e-07	3.16e-06	CbGpPWpGaD
